Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
February 17, 2017

Recent Stories

From Drug Benefit News - CMS is planning changes to the way it tracks opioid overuse and calculates the post-discharge medication reconciliation measure beginning in 2018, the agency said in its annual Advance Notice and draft Call Letter posted Feb. 1. The proposed changes are among numerous tweaks to stand-alone Part D Prescription Drug Plans (PDPs) and Medicare Advantage prescription drug (MA-PD) plans outlined in the 159-page document. CMS also proposed small adjustments in Part D benefit parameters and in some star rating measures. Comments on the changes are due to CMS on March 3. Read more

As specialty drug costs continue to rise and show few signs of… Read more

Pharmacy benefit managers Express Scripts Holding Co. and CVS Health could be… Read more

The manufacturer of an insulin autoinjector is once again in the crosshairs… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

January 17, 2017
Long-Awaited Biosimilar Interchangeability Draft Guidance Is Out

FDA finally unveils interchangeability draft guidance for biosimilars, expects “that applications generally will include data from a switching study or studies in one or more appropriate conditions of use,” among other criteria

January 12, 2017
FDA Finalizes Naming Guidance for Biologics, Biosimilars

In final guidance, FDA says all biologics, not only biosimilars, will have four-letter suffixes; agency still considering “appropriate suffix format” for interchangeable biosimilars

December 28, 2016
FDA Issues More Biosimilar Guidance

FDA issues guidance on clinical pharmacology data needed to show a product is biosimilar to its reference drug

It's quick and easy to sign up for FREE access to!

Why do I need to register?